Elemental analysis and trace metals testing supporting pharmaceutical development and GMP production through elemental composition and impurity quantification testing services from GMP laboratories

Elemental analysis and trace metals testing of pharmaceuticals is critical to drug product quality control and commercial release. Understanding the elemental composition of your raw materials, active pharmaceutical ingredients (APIs), excipients or formulations helps to ensure product quality and purity. Where the elemental composition is unknown, a strategic approach, which rationalises effort and spend, is required. 

Trace metals are known to be toxic and can affect the stability of a formulation and catalyst degradation. Accordingly, control during the manufacturing process is important. The presence of trace species at very low levels and samples with poor solubility can all present analytical challenges to elemental analysis.

Our elemental testing and analysis experts have significant experience in pharmaceutical organic and inorganic elemental analysis with coverage of almost the entire periodic table from trace levels to percent levels. Trace metals elemental testing is a routine activity for our Good Manufacturing Practice (GMP) laboratories and is carried out in accordance with pharmacopeia methods such as the United States Pharmacopeia (USP) Chapters USP 232 and USP 233  for elemental impurities or to client specific methods. We also provide combined toxicological risk-assessment and testing compliance services to meet the requirements of ICH Q3D Guidelines for Elemental Impurities.

Our experienced analysts apply a strategic approach to sample preparation for difficult samples and a range of analytical technology, relevant to your needs, including inductively coupled plasma – mass spectrometry (ICP-MS) or inductively coupled plasma – optical emission spectroscopy (ICP-OES), ion chromatography (IC), flame atomic absorption spectroscopy (FLAA) and X-ray fluorescence (XRF).

In accordance with the latest regulatory developments our experts design the most suitable, phase-appropriate, analytical package for your product. For 21CFR Part 210 and 211 to support the release of finished products, stability, reference standard certification and clinical trials support, we offer method development and validation where required, pharmaceutical analysis or pharmaceutical impurity testing via validated analytical methods and acceptance criteria to support the intended use. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards. 

Related Links

Spotlight - Elemental

Requirements for Elemental Impurities Testing

Oligonucleotide News

White paper download: Analytical Strategies for Oligonucleotides
Contact Intertek